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Abstract
Cardiovascular disease is the major cause of morbidity and mortality associated with diabetes.
There is increasing evidence that advanced glycation endproducts (AGEs) play a pivotal role in
atherosclerosis, in particular in diabetes. AGE accumulation is a measure of cumulative metabolic
and oxidative stress, and may so represent the "metabolic memory". Furthermore, increased AGE
accumulation is closely related to the development of cardiovascular complications in diabetes. This
review article will focus on the clinical relevance of measuring AGE accumulation in diabetic
patients by focusing on AGE formation, AGEs as predictors of long-term complications, and
interventions against AGEs.
Background
Patients with diabetes have a mortality rate from cardio-
vascular disease (CVD) that is over twice compared to that
in the general population [1]. The Adult Treatment Panel
III regards diabetes as a coronary heart disease risk equiv-
alent. A number of hemodynamic and metabolic factors
co-operate in diabetes [2]. Both the Diabetes Control and
Complications Trial (DCCT) in type 1 diabetes mellitus
and the UK Prospective Diabetes Study (UKPDS) in type
2 diabetes mellitus established a causal relationship
between chronic hyperglycemia and long-term diabetic
complications [3,4]. There is increasing evidence that
advanced glycation endproducts (AGEs) play a pivotal
role in atherosclerosis, in particular in diabetes. AGE accu-
mulation is not just a measure of hyperglycemia, but rep-
resents cumulative metabolic burden (both
hyperglycemia and hyperlipidemia), oxidative stress and
inflammation [5]. Interaction between AGEs and AGE-
specific receptors induce inflammatory reactions and
endothelial dysfunction [6]. This review will focus on the
clinical merits of assessing AGE accumulation in diabetic
patients, outlining the evidence for the role of AGEs in the
pathogenesis of CVD and the possibilities for AGE-inter-
vention. Finally, we will discuss the clinical relevance for
assessing AGE accumulation.
AGE formation
The original Maillard hypothesis on the formation of
AGEs proposed that chemical modification of proteins by
reducing sugars (glycation of proteins) in diabetes alters
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the structure and function of tissue proteins, precipitating
the development of diabetic complications (Fig. 1) [7].
Glycation involves the formation of chemically reversible
early glycosylation products with proteins, so called Schiff
bases and Amadori adducts (e.g. glycated hemoglobin;
HbA1C). With time, it became clear that these early
adducts undergo slow and complex rearrangements to
form advanced glycation end-products (AGEs). Baynes
and colleagues noted the importance of oxidizing condi-
tions and reactive oxygen species in the formation of gly-
coxidation products, the major class of AGEs that
accumulate in tissues in diabetes [5]. Besides the forma-
tion of carbohydrate intermediates, there is increasing evi-
dence that Maillard products are also formed via lipid-
derived intermediates, resulting in advanced lipoxidation
products (ALEs)[8]. Dyslipidemia is a common phenom-
enon in diabetes and lipids are an important source of
protein modifications. So, in diabetic patients both AGEs
and ALEs may be formed at the same time in atheroscle-
rotic plaques.
Other pathways which may lead to AGE formation is
through autoxidation of glucose by reactive oxygen spe-
cies, and through carbonyl compounds [9,10]. In particu-
lar methylglyoxal, a reactive dicarbonyl metabolite of
glucose, has received considerable attention as the most
reactive AGE precursor in endothelial cells. Decreased
clearance of serum AGEs may further increase tissue AGE
accumulation and de novo formation, and absorption of
AGEs from food or smoking may aggravate AGE accumu-
lation in renal failure [11-13].
Simplified scheme of the complex Maillard reaction and formation of some advanced glycation endproducts (AGEs) in vivo Figure 1
Simplified scheme of the complex Maillard reaction and formation of some advanced glycation endproducts 
(AGEs) in vivo. CEL = carboxyethyllysine; MOLD = methylglyoxal lysine dimer; DOLD, 3-deoxyglucosone lysine dimer; 
CML, carboxymethyllysine; GOLD, glyoxal lysine dimer.Cardiovascular Diabetology 2008, 7:29 http://www.cardiab.com/content/7/1/29
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Assessment of AGE accumulation
The characteristic fluorescence spectrum of AGEs at 440
nm upon excitation at 370 nm has classically been used to
determine tissue AGE accumulation [14]. Later biochemi-
cal and immunochemical assays measure both fluorescent
AGEs, like pentosidine, and non-fluorescent AGEs, like
carboxymethyl-lysine (CML) [15,16]. Complexity, cost
and lack of reproducibility contributed to limiting
broader use of these latter assays. In recent years, tandem
mass spectrometry has considerably facilitated the use
and improved the reproducibility of the assay for several
AGEs.
Moreover, blood and urine sampling of AGE do not nec-
essarily reflect tissue AGE levels [17,18]. After the forma-
tion of AGEs, the accumulation of AGEs bound to
proteins is dependent on the half-life of these proteins.
On long-lived proteins like skin collagen, lens crystallins
and in cartilage proteins, they even accumulate over the
lifetime of organisms. Importantly, the sites where
chronic complications develop in diabetes are also those
where long-lived proteins are present (e.g. glomerular
basement membrane, lens crystalline). It seems therefore
appropriate to prefer assays of tissue AGE accumulation
rather than e.g. plasma samples.
Noninvasive techniques to analyze tissue AGE accumula-
tion, such as lens or skin autofluorescence have also been
described. For instance, lens autofluorescence (excitation
350–370 nm, emission 430–450) is significantly higher
for diabetic patients than for age-matched control sub-
jects, and the lens autofluorescence increases significantly
with the progression of diabetic retinopathy [19]. Several
years ago, we developed an instrument, the AGE-reader,
designed to noninvasively measure skin autofluorescence.
Several studies have shown that skin autofluorescence
measured with the AGE-reader is strongly related to AGE
accumulation in healthy subjects, diabetic patients and
hemodialysis patients [20-22]. Also others have shown an
increased skin autofluorescence in relation to AGE accu-
mulation and the screening for type 2 diabetes [23].
AGE accumulation and CVD
Diabetic patients have a clearly increased risk of cardio-
vascular morbidity and mortality. Both the DCCT and the
UKPDS have shown that hyperglycemia contributes to the
increased cardiovascular risk [3,4]. AGEs play an impor-
tant role in the development and progression of cardio-
vascular disease in diabetes. Serum levels of AGEs in
patients with type 2 diabetes with coronary heart disease
(CHD) are increased compared to patients without CHD,
and correlate with CHD severity [24]. Even after correc-
tion for other cardiovascular risk factors, remain serum
AGE levels associated with CHD. AGE deposits have been
demonstrated in atherosclerotic plaques and within myo-
cardium fibers [25,26]. Serum levels of AGEs in type 1 dia-
betic patients are associated with isovolumetric relaxation
time of the left ventricle, as a marker of left ventricular
diastolic dysfunction [27].
AGE levels are further related to other features of CVD,
such as carotid stenosis and peripheral artery occlusive
disease. AGE levels are higher in type 2 diabetic patients
with peripheral artery occlusive disease compared to those
without [28]. Furthermore, AGE contents are correlated to
ankle-brachial index, also after correction for other cardi-
ovascular risk factors. The EURODIAB prospective com-
plication study showed a strong correlation between pulse
pressure and plasma levels of AGEs in type 1 diabetic
patients [29]. Endogenous secretory receptor for AGEs
(esRAGE) binds to AGEs and is capable of neutralizing
AGE action. In type 1 diabetic patients, circulating
esRAGE is inversely correlated with carotid IMT [30].
Koyama et al also observed an inverse relationship
between esRAGE and carotid IMT in type 2 diabetic
patients and non-diabetic subjects [31]. In humans, RAGE
overexpression has been associated with enhanced
inflammatory reactions at the vulnerable region of the
plaque in carotid endarterectomy specimen [32] In an
intervention study it has been shown that statin treatment
prior to carotid endarterectomy reduces inflammation as
well as RAGE expression [33].
AGEs are not only related to manifestations of CVD, but
they also provide prognostic information. Table 1
describes the studies that observed a strong relationship
Table 1: AGEs and the prediction of cardiovascular disease
Author Year n FU (yr) Tissue Complication
Simm [34] 2007 75 - Pericardial Perioperative cardiac events
Koyama [71] 2007 141 1,5 Serum Cardiac events (heart failure)
Hartog [38] 2007 102 1,7 Serum Cardiac events (heart failure)
Kilhovd [37] 2007 386 18 Serum Cardiac mortality
Meerwaldt [22] 2005 109 3 Skin Cardiovascular mortality
Meerwaldt [36] 2007 117 5 Skin Cardiovascular mortality
n = number of patients, FU = follow-up in years, Tissue = tissue in which AGE content was measured.Cardiovascular Diabetology 2008, 7:29 http://www.cardiab.com/content/7/1/29
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between AGE levels and the development of CVD. Simm
et al showed that AGE content correlates with poor out-
come as shown by adverse cardiac events in patients after
cardiac surgery [34]. AGEs show an inverse relationship
with left ventricular ejection fraction, and furthermore
correlate with prolonged ventilation time and prolonged
stay at the Intensive Care Unit. AGE levels may not only
predict operative outcome, but also the success rate of
interventions. In diabetic patients receiving cardiac stents
an elevated level of serum AGEs appeared to be an inde-
pendent risk factor for the development of angiographic
re-stenosis [35].
During long-term follow-up we observed that skin
autofluorescence is a strong predictor of survival in dia-
betic patients [22,36]. Increased serum levels of AGEs pre-
dict total, cardiovascular and coronary mortality in
women with type 2 diabetes during a follow-up period of
18 years [37]. AGE level remained a strong predictor of
survival, even after adjustment for confounding factors,
including C-reactive protein. We and others have demon-
strated that serum AGE levels are predictors for heart fail-
ure and new cardiac events [38,39].
Figure 2 shows the mechanisms by which AGEs may con-
tribute to long-term complications. AGEs may especially
promote CVD in diabetes through endothelial dysfunc-
tion, inflammation, and inducing lipid abnormalities.
AGE accumulation may be related to endothelial dysfunc-
tion, and endothelial RAGE has been proposed as the
major key in such an interaction. Binding of AGEs to
RAGE activates endothelial cells, resulting in higher levels
of endothelial adhesion molecules like VCAM-1, and acti-
vation of transcription factor NF-kB [40]. Endothelial
adhesion molecules and NF-kB further increase monocyte
adhesivity and vascular permeability, accelerating athero-
sclerosis [41]. AGEs initiate inflammation-mediated pro-
liferative processes and propagate inflammation in
established macrovascular disease [42-44]. Through the
interaction with RAGE, AGEs induce oxidative stress.
AGEs also induce inflammation by modifying low density
lipoproteins, limiting their clearance, promoting uptake
by macrophages [45,46].
AGE accumulation and microvascular 
complications
Monnier et al first described the relation between AGE
accumulation in skin collagen and the severity of long-
term diabetic complications [14]. Beisswenger and others
have shown that AGE accumulation precedes and corre-
lates with early manifestations of renal disease [47].
Genuth et al were the first to show in type 1 diabetic
patients that skin collagen AGE levels (especially car-
boxymethyllysine) are strong predictor for the develop-
ment and progression of microvascular complications
including nephropathy [48]. Interestingly, the effects of
skin AGEs were independent of the preceding HbA1c or
those later present during progression of these complica-
tions. We recently showed that skin autofluorescence,
even after correction for other risk factors, is a strong and
independent predictor for the development of microvas-
cular complications, including nephropathy in type 2 dia-
betic patients [49]. AGEs have a predictive value for the
development of microvascular complications, which was
found to be superior to other common risk predictors,
such as diabetes duration and HbA1c. These results were
applicable for primary care type 2 diabetic patients,
treated according to current standards. Interestingly, tis-
sue AGE levels prove superior to (single) HbA1c measure-
ments in predicting the progression of diabetic
Pathogenetic effects of advanced glycation endproducts (AGEs) Figure 2
Pathogenetic effects of advanced glycation endproducts (AGEs). By binding and crosslinking extracellular matrix, e.g. 
collagen, AGEs induces vascular stiffness en increases vascular permeability. The interaction with AGE receptors (e.g. RAGE) 
induces endothelial dysfunction by reducing nitric oxide (NO), inflammatory reactions, and oxidative stress. Binding to lipopro-
teins increases the uptake of e.g. low density lipoproteins (LDL) by macrophages, which may lead to the formation of foam 
cells.Cardiovascular Diabetology 2008, 7:29 http://www.cardiab.com/content/7/1/29
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complication [50], as AGE levels may provide a measure
of tissue damage resulting from overall metabolic burden,
instead of specific risk factors per se [51]. AGE levels in
skin collagen predict the risk of future progression of dia-
betic complications, independently of HbA1c.
Recently, we observed that AGE levels are related to both
peripheral and autonomic neuropathy, even before clini-
cal manifestations of neuropathy [52]. Furthermore, skin
AGE accumulation is strongly related to the severity of
neuropathic foot ulceration. Microvascular disease may
worsen ulceration, and endothelial dysfunction has been
demonstrated in relation to both diabetic neuropathy and
foot ulceration [53]. AGE accumulation has also been
reported to worsen endothelial function, and endothelial
RAGE has been proposed as the major key in such interac-
tion. Blockage of RAGE accelerates wound closure in dia-
betic mice and suppresses levels of cytokines such as
tumor necrosis factor [54].
AGE-intervention
Interventions possible against AGE formation and AGE-
mediated damage are numerous. Intensive glycemic con-
trol in patients from the DCCT trial led to a lower risk for
diabetic microvascular complications compared to con-
ventional treatment [3]. The lower risk was associated
with lower AGE levels, even after adjustment for HbA1c
[3,55]. The discovery of chemical agents that can inhibit
glycation reactions may have potential great therapeutic
importance. For instance, pyridoxamine, has been shown
to inhibit AGE formation and the formation of lipid-
derived Maillard products; advanced lipoxidation end-
products (ALEs) [56]. Pyridoxamine is one of the natural
forms of vitamin B. It does not directly interact with Ama-
dori products, but interferes with the post-Amadori oxida-
tive reactions. Furthermore, pyridoxamine traps reactive
carbonyl compounds, inhibiting AGE and ALE adducts.
Pyridoxamine inhibits the development of renal and vas-
cular complications in obese rats [57]. Clinical trials eval-
uating the efficacy of pyridoxamine in inhibiting the
progression of proteinuria and hyperlipidemia in diabetic
patients are ongoing. Benfotiamine is a lipophilic derivate
of vitamin B1. Its proposed mechanism of action is shunt-
ing glycolytic intermediates to the reductive pentose path-
way. Benfotiamine reduces the effect of an AGE-rich diet
on endothelial dysfunction in type 2 diabetic patients
[58].
Another approach has been focused on the cleavage of
already formed AGEs protein-protein crosslinks.
Although AGE breakers have shown to break AGE-protein
crosslinks in vitro, their beneficial effects in trials may not
necessarily or exclusively be related to this breaking effect.
Compounds like 4,5-dimethyl-3 phenacylthiazolium,
also known as ALT-711, have been widely tested. AGE-
breakers have been shown to break preformed AGE
crosslinks, and to improve arterial compliance in a phase
2 clinical trial in elderly [59]. Currently, clinical trials in
heart failure are ongoing (e.g. BENEFICIAL study).
While there are several pharmacological agents specifi-
cally aiming at AGEs, there are also "more common"
agents that may also reduce AGE accumulation. Interest-
ingly, antihypertensives, such as angiotensin converting
enzyme (ACE) inhibitors and angiotensin receptor block-
ers, reduce AGE accumulation in concert with the severity
of diabetic nephropathy [60-62]. Metformine is another
examples which has additional effects on AGE accumula-
tion, e.g. by reducing oxidative stress [62-65]. Guanidine
compounds block dicarbonyl groups, and metformine
(diamino biguanide compound) may decrease AGE accu-
mulation by reducing methylglyoxal levels [66]. Further-
more, metformine is a scavenger of reactive oxygen
species [67]. Metformine treatment improves endothelial
function in type 2 diabetes and this effect is independent
of the antihyperglycemic properties of metformine [68].
Importantly, in the past, clinical evaluation of AGE inhi-
bition has been limited due to concern about long-term
toxicity. An important aim of ongoing trials is to monitor
unexpected side effects. Without important information
on safety or clinical efficacy, trials have mostly focused on
patients with long-term complications instead of analyz-
ing primary prevention in diabetic patients.
AGEs and clinical relevance in diabetes
Table 2 and 3 summarize the potential clinical relevance
and a future perspective of assessing AGE accumulation in
diabetes. AGE accumulation is a strong predictor for the
development and progression of long-term complica-
tions, as described above. Many studies observed that AGE
Table 2: Clinical relevance of advanced glycation endproducts (AGEs)
Measure of long-term cumulative metabolic stress
AGEs as a mechanism for the "metabolic memory" observed in diabetes
Measure of oxidative stress (e.g. from smoking) and its' interaction with metabolic stress
Shows the resulting protein damage from various cardiovascular risk factors
AGEs are independent predictors of cardiovascular complications and mortality
Perioperative risk (e.g. cardiac events, pulmonary complications) is related to AGEs
AGEs may help in monitoring and tailoring diabetes treatmentCardiovascular Diabetology 2008, 7:29 http://www.cardiab.com/content/7/1/29
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levels were related to these events independent of HbA1c,
or even found no contribution of HbA1c as a predictor for
complications. This might in part be explained by the con-
cept that tissue AGE accumulation reflects cumulative
metabolic stress (i.e. metabolic memory) rather than
short term glycemic control (HbA1c). AGE accumulation
is not just a measure of metabolic stress, but also incorpo-
rates oxidative and carbonyl stress. In other words, it
shows protein tissue damage resulting from many risk fac-
tors for cardiovascular disease.
It is also important to stress that there is a major overlap
in (increased) cardiovascular risk between persons with
impaired (fasting) glucose tolerance and type 2 diabetes.
The diagnosis of diabetes is also not a fixed diagnosis over
time in e.g. an obese patient who manages to reduce
weight considerably. If metabolic imbalances are stronger
determining factors for cardiovascular risk than momen-
tary glucose levels, or than a diagnosis of diabetes, this
supports a role for assessing AGE accumulation.
Measuring tissue AGE levels may be useful in monitoring
and tailoring diabetes treatment. Many patients already
use for example statins, ACE inhibitors, or metformine,
which all may reduce AGE accumulation. Unfortunately,
clinical trials evaluating the effect of specific AGE inhibi-
tors or breakers are limited or still in progress. Some early
trials were hampered by side effects of these pharmacolog-
ical agents (e.g. vitamin B6 deficiency syndrome) [69].
The question remains whether AGEs are a risk factor for
CVD in the long run, or that AGEs are also a measure of
current CVD activity. If AGE levels help to identify the dia-
betic patient with unstable cardiovascular disease, this
may definitely increase the clinical relevance. Epidemio-
logical studies investigating AGE levels as a marker of vul-
nerable plaques are lacking. Nevertheless, we recently
observed that skin autofluorescence is an independent
marker of acute myocardial infarction and it predicts
major adverse cardiac events one year after acute myocar-
dial infarction (personal data: Mulder et al., American
Heart Association 2006). Interestingly, skin autofluores-
cence was strongly related to markers of inflammation
and oxidative stress.
Finally, it is important for clinicians to critically appraise
the value of new cardiovascular risk factors. As described
by Morrow et al., the value of new risk factors may be
structured around three issues: can we measure the risk
factor, does it add new information and does it help to
manage patients [70]? AGEs can be measured as described
above, although limitations remain. AGE levels add new
information for the development and progression of car-
diovascular disease in both diabetic and non-diabetic
patients. Studies to test whether AGE levels really help to
manage diabetic patients in daily practice are now in
progress.
Conclusion
AGEs have been implicated in the pathogenesis of long-
term complications in diabetes. Animal and in vitro
research has shown that AGEs affect extracellular proteins
and activate cytokine production and transcription factors
via binding to AGE receptors. AGE accumulation closely
correlates with the severity and predicts the development
of cardiovascular complications. A variety of interventions
against AGE accumulation, predominantly tested in pre-
clinical contexts, appear to show beneficial effects on the
development/progression of diabetic complications.
Findings from current clinical trials, including feasibility
studies, may further help in determining the relevance of
AGE assessment in diabetes.
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